LDLR and neoplasm: Third, biomarkers and predictors of response and resistance to PCSK9 inhibition and anti-PD-1/PD-L1 immunotherapy, such as PCSK9 expression, LDLR expression, MHC I expression, the TCR repertoire, and tumor mutational burden, need to be identified and validated.